PharmaShots | Incisive News in 3 Shots

Subscribe Now

high-risk non-muscle invasive bladder cancer

Merck Receives the US FDA Advisory Committee's Recommendation on Approval of Keytruda (pembrolizumab) for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Merck Receives the US FDA Advisory Committee's Recommendation on Approval of Keytruda (pembrolizumab) for Patients with High-Risk...

December 18, 2019

Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NM...

December 2, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us